Respiri Ltd
ASX:RSH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (56.2), the stock would be worth AU$0.06 (61% upside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 34.9 | AU$0.04 |
0%
|
| 3-Year Average | 56.2 | AU$0.06 |
+61%
|
| 5-Year Average | 109.8 | AU$0.11 |
+214%
|
| Industry Average | 3.1 | AU$0 |
-91%
|
| Country Average | 5.8 | AU$0.01 |
-83%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
R
|
Respiri Ltd
ASX:RSH
|
55.1m AUD | 34.9 | -7.3 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
162.6B USD | 23.6 | 56.9 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
155.4B USD | 6.1 | 24.8 | |
| US |
|
Stryker Corp
NYSE:SYK
|
112.7B USD | 7.6 | 34.7 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
102.7B USD | 5.3 | 22.3 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
83.8B USD | 6.5 | 23.5 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.8B USD | 9.2 | 44.5 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.3B EUR | 5.2 | 18.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.2B USD | 17.1 | 42.7 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.5B USD | 5.8 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
29.9B USD | 8.8 | 20.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 3.4 |
| Median | 5.8 |
| 70th Percentile | 11.1 |
| Max | 27 768.2 |
Other Multiples
Respiri Ltd
Glance View
Respiri Ltd. engages in research, development, and commercialization of medical devices and the production of mobile health applications for management of asthma and related chronic respiratory diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2000-07-14. The firm's segments include Australia and Israel. The Australia segment is engaged in research, development and commercialization of medical devices, and the production of mobile health applications in Australia. The Israel segment is engaged in research, development and commercialization of medical devices, and the production of mobile health applications in Israel. The firm has developed a wheezo, which is an eHealth Saas platform that uses a device and app to measure, record and assist asthma monitoring. Its device and app make up a cloud-based mobile health platform that records wheeze and other clinically relevant symptoms and signs of asthma.
